FOXP3 and pancreatic neoplasm: In pancreatic cancer patients, FoxP3+IL-10+TGF-β+ TI Tregs comprised 12% of the ENO1-specific CD4+ T cell population and specifically inhibited the proliferation of autologous ENO1-specific Teff [46].